Genelux (GNLX) Convertible Debt (2022 - 2023)

Genelux's (GNLX) quarterly Convertible Debt came in at $40000.0 in Q3 2023, down 38.46% quarter-over-quarter from $65000.0 in Q2 2023.

Genelux (GNLX) Convertible Debt (2022 - 2023) Analysis & Trends

Genelux's Convertible Debt history runs 2 years deep, the most recent figure standing at $40000.0 for Q3 2023.

On a quarterly basis, Convertible Debt changed N/A year-over-year to $40000.0 in Q3 2023; TTM through Sep 2023 was $40000.0, a N/A change from a year earlier, with the FY2022 full-year figure at $15.4 million, changed N/A from the prior year.
Convertible Debt retreated to $40000.0 in Q3 2023 per GNLX's latest filing, from $65000.0 in the prior quarter.
Across five years, Convertible Debt topped out at $15.4 million in Q4 2022 and bottomed at $40000.0 in Q3 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn
7	Belite Bio	62.72 Bn	62.72 Bn	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn
9	Revolution Medicines	37.35 Bn	37.35 Bn	-
10	Genelux	129.36 Mn	129.36 Mn	-

Download Data